91 196

Cited 4 times in

The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer

Authors
 Byoung Chul Cho  ;  Joo Hang Kim  ;  Ross A Soo  ;  Chih-Hsin Yang 
Citation
 YONSEI MEDICAL JOURNAL, Vol.51(1) : 1-8, 2010 
Journal Title
 YONSEI MEDICAL JOURNAL 
ISSN
 0513-5796 
Issue Date
2010
MeSH
Antibodies, Monoclonal/therapeutic use* ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/therapeutic use* ; Asian Continental Ancestry Group ; Bevacizumab ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Cetuximab ; Humans
Keywords
Non-small cell lung cancer ; bevacizumab ; cetuximab ; chemotherapy ; monoclonal antibody
Abstract
The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting.
Files in This Item:
T201000058.pdf Download
DOI
10.3349/ymj.2010.51.1.1
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Joo Hang(김주항)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100402
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse